共 50 条
- [1] Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl- coenzyme a reductase inhibitor treatment of combined dyslipidemiaMETABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (10): : 1355 - 1359McLaughlin, TAbbasi, FLamendola, CLeary, EReaven, GM
- [3] HMG-CoA reductase inhibitors and fibric acid derivatives: A dangerous combination for the treatment of hyperlipidemiaJOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1999, 47 (09) : S81 - S81Morales, CEBruzzi, JFChilson, TSHurley, DL
- [4] Drug treatment of hyperlipidemia in the elderly: HMG-CoA reductase inhibitors and fibric acid derivativesDRUGS AFFECTING LIPID METABOLISM: RISK FACTORS AND FUTURE DIRECTIONS, 1996, 10 : 459 - 464Zambon, ABaggio, GCrepaldi, G
- [6] TOWARDS A NEW TYPE OF HMG-COA REDUCTASE INHIBITORTETRAHEDRON, 1990, 46 (19) : 6731 - 6740BARTH, MBELLAMY, FDRENAUT, PSAMRETH, SSCHUBER, F
- [8] HYPERKALEMIA DURING TREATMENT WITH HMG-COA REDUCTASE INHIBITORNEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (18): : 1219 - 1220EDELMAN, SWITZTUM, JL
- [9] HMG-CoA reductase inhibitor treatment in renal insufficiencyNEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (10) : 1951 - 1952Wanner, C
- [10] Effectiveness of pitavastatin, an HMG-CoA reductase inhibitor, on lipid and glucose metabolism in Japanese patients with type 2 diabetesDIABETES, 2006, 55 : A461 - A461Kawai, ToshihideTokui, MikiyaFunae, OsamuMeguro, ShuYamada, SatoruTabata, MitsuhisaShimada, Akira